Retired Compendial Notices Prior to 2010

<1> Proposed Revisions to the Labeling on Ferrules and Cap Overseals Section of General Chapter <1> Injections (posted 24–Nov–2009)
<1> Injections: Notice of Intent to Revise (posted 29–Jul–2009)
<1> Injections—USP Announcement on Labeling on Ferrules and Cap Overseals Section (posted 08–May–2009)
<1> First Supplement to USP 31–NF 26 includes an incorrect General Chapter: <1> Injections (posted 07–Apr–2008)
<3> and <725> Topical and Transdermal Products—USP Forwards Proposed General Chapters on Topical and Transdermal Drug Products (posted 29–May–2009)
<55> Second Supplement to USP 31–NF 26 Online and CD includes an incorrect version of USP General Chapter <55> Biological (posted 23–Jul–2008)
<61> and <62>: First Supplement USP 31–NF 26 included three errors in USP General Chapters <61> and <62> (posted 15–Aug–2008)
<232> <233> <1232>: Metal Impurities Advisory Panel Recommendations to the General Chapters Expert Committee (posted 02–Jun–2009)
<381> Elastomeric Closures for Injections—Error in USP 32–NF 27 Publication Dates (posted 03–Dec–2008)
<467> Residual Solvents/Organic Volatile Impurities (posted 15–Jun–2007)
<467> Frequently Asked Questions about <467> Residual Solvents
<643> Total Organic Carbon Comment Period Extension (posted 17–Oct–2007)
<671> Containers—Performance Testing: Notice of Intent to Revise (posted 1–Dec–2007)
<711> Dissolution: Notice of Intent to Revise (posted 11–Mar–2008)
<725> and <3> Topical and Transdermal Products–USP Forwards Proposed General Chapters on Topical and Transdermal Drug Products (posted 29–May–2009)
<797> Errata Corrected in Revised General Chapter <797> (posted 28–Jan–2008)
<905> Uniformity of Dosage Units (posted 20–Apr–2007)
<1121> Nomenclature: Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations (posted 04–Jun–2007; official 01–May–2013)
<1151> Pharmaceutical Dosage Forms (posted 06–Oct–2009)
Acitretin Capsules (posted 22–Jul–2009)
Alendronate Sodium Tablets: Notice of Intent to Revise (posted 01–Feb–2008)
Cephalexin Monographs (posted 07–Dec–2009; revised 30–Jun–2010)
Changes to the Dissolution Performance Verification Test (posted 20–Nov–2009)
Coordination of Official New Monographs, Revisions, and USP Reference Standards (posted 20–Feb–2006)
Coordination of PF Submissions and New USP Reference Standards (posted 03–Apr–2006)
Correction to Pharmacopeial Forum 34(2) (posted 07–Mar–2008)
Estradiol Vaginal Inserts (posted 07–Dec–2009)
Galantamine Tablets: Notice of Intent to Revise (Reposted) (posted 12–Jun–2009)
Galantamine Tablets (posted 01–Aug–2008)
Green Tea Cautionary Labeling Update (posted 10–Apr–2009)
Heparin: Notice of Heparin Stage 2 Interim Revision Announcements (posted 24–Jun–2009)
Heparin and Enoxaparin Monographs: Stage 2 Web Postings Supersede Printed Monographs in USP 33–NF 28 (posted 22–Dec–2009)
Levalbuterol Hydrochloride (posted 29–May–2009)
Levothyroxine Sodium Tablets (posted 29–Aug–2008; official 03–Oct–2009)
Metal Impurities Advisory Panel Recommendations to the General Chapters Expert Committee (posted 02–Jun–2009)
Missing Page Numbers in Auxiliary Information from Eight Chapters (posted 10–Sep–2008)
Modafinil (posted 19–Jun–2009)
Modafinil Tablets (posted 19–Jun–2009)
Nefazodone Hydrochloride (posted 20–Mar–2009)
New USP Reference Standards (posted 07–Mar–2007)
Prospective Harmonization (posted 09–Nov–2009)
Recent Modifications to the USP Standards–Setting Process (posted 17–Jul–2007)
Revision to USP Pending Monographs Guideline (posted 09–Nov–2009)
Six-Month Implementation Guideline (posted 09–Nov–2009)
Sodium Fluoride and Acidulated Phosphate Topical Solution: Notice of Intent to Revise (posted 07–Mar–2007)
Tamsulosin Hydrochloride Capsules: Notice of Intent to Revise (posted 08–Apr–2009)
Tazobactam: Notice of Intent to Revise (posted 29–Feb–2008)
USP 32–NF 27 Commentary Amended (posted 19–Mar–2009)
USP 33–NF 28 Errata (posted 17–Nov–09)
USP Invites Public Comments on its Dietary Supplement Safety Review Process (posted 03–Dec–2008)
USP Performance Test and the Dissolution Procedure Statement (posted 24–Oct–2006)
USP Releases Improved Packaging for Salicylic Acid Calibrator Tablets (posted 19–Oct–2005)
USP Revises its Request for Revision Guideline (posted 24–July–2009)
USP Statement on Prednisone Tablets: Notice of Change in Performance (posted 10–Oct–2007)